| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 169.61% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 10/31/2023 | 169.61% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 10/26/2023 | 169.61% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 10/05/2023 | — | Truist Securities | Downgrades | Buy → Hold | |
| 09/13/2023 | 169.61% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 09/08/2023 | 169.61% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 08/28/2023 | 169.61% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 08/23/2023 | -1.96% | Mizuho | → $4 | Reiterates | Neutral → Neutral |
| 08/18/2023 | 169.61% | HC Wainwright & Co. | $60 → $11 | Maintains | Buy |
| 08/15/2023 | -1.96% | Goldman Sachs | $12 → $4 | Maintains | Neutral |
| 08/15/2023 | -1.96% | Mizuho | $40 → $4 | Downgrades | Buy → Neutral |
| 08/15/2023 | 659.8% | Truist Securities | $71 → $31 | Maintains | Buy |
| 08/15/2023 | 390.2% | Canaccord Genuity | $75 → $20 | Maintains | Buy |
| 07/17/2023 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 07/03/2023 | 1370.59% | HC Wainwright & Co. | $66 → $60 | Maintains | Buy |
| 06/30/2023 | 880.39% | Mizuho | → $40 | Reiterates | Buy → Buy |
| 05/30/2023 | 1517.65% | HC Wainwright & Co. | → $66 | Reiterates | Buy → Buy |
| 05/26/2023 | 512.75% | Goldman Sachs | $28 → $25 | Maintains | Neutral |
| 05/17/2023 | 1517.65% | HC Wainwright & Co. | → $66 | Reiterates | Buy → Buy |
| 05/11/2023 | 1517.65% | HC Wainwright & Co. | → $66 | Reiterates | Buy → Buy |
| 05/10/2023 | 880.39% | Mizuho | $38 → $40 | Maintains | Buy |
| 05/09/2023 | 1027.45% | Guggenheim | $50 → $46 | Maintains | Buy |
| 03/21/2023 | 1517.65% | HC Wainwright & Co. | $79 → $66 | Maintains | Buy |
| 03/10/2023 | 439.22% | Jefferies | $20 → $22 | Downgrades | Buy → Hold |
| 02/27/2023 | 1836.27% | HC Wainwright & Co. | → $79 | Reiterates | → Buy |
| 02/21/2023 | 1836.27% | HC Wainwright & Co. | $73 → $79 | Maintains | Buy |
| 02/08/2023 | 831.37% | Mizuho | $24 → $38 | Maintains | Buy |
| 01/26/2023 | 537.25% | Goldman Sachs | $16 → $26 | Maintains | Neutral |
| 01/03/2023 | 1689.22% | HC Wainwright & Co. | $85 → $73 | Maintains | Buy |
| 12/01/2022 | 292.16% | Goldman Sachs | → $16 | Upgrades | Sell → Neutral |
| 11/16/2022 | 341.18% | Mizuho | $19 → $18 | Maintains | Buy |
| 11/11/2022 | 512.75% | Guggenheim | $28 → $25 | Maintains | Buy |
| 11/11/2022 | 1762.75% | Canaccord Genuity | $75 → $76 | Maintains | Buy |
| 11/11/2022 | 341.18% | Mizuho | $19 → $18 | Maintains | Buy |
| 08/24/2022 | 1983.33% | HC Wainwright & Co. | $110 → $85 | Maintains | Buy |
| 07/07/2022 | 365.69% | Mizuho | → $19 | Initiates Coverage On | → Buy |
| 05/23/2022 | 2596.08% | HC Wainwright & Co. | $134 → $110 | Maintains | Buy |
| 05/09/2022 | 145.1% | Goldman Sachs | $17 → $10 | Maintains | Sell |
| 04/14/2022 | 3184.31% | HC Wainwright & Co. | $130 → $134 | Maintains | Buy |
| 03/14/2022 | 3086.27% | HC Wainwright & Co. | $140 → $130 | Maintains | Buy |
| 02/16/2022 | 512.75% | UBS | $88 → $25 | Maintains | Buy |
| 11/15/2021 | 488.24% | Goldman Sachs | $55 → $24 | Downgrades | Buy → Sell |
| 06/28/2021 | 3331.37% | HC Wainwright & Co. | $176 → $140 | Maintains | Buy |
| 06/23/2021 | 2963.73% | Truist Securities | $128 → $125 | Maintains | Buy |
| 06/01/2021 | 4213.73% | HC Wainwright & Co. | $170 → $176 | Maintains | Buy |
| 05/11/2021 | 4066.67% | HC Wainwright & Co. | $175 → $170 | Maintains | Buy |
| 04/09/2021 | 1738.24% | Berenberg | → $75 | Initiates Coverage On | → Buy |
| 04/01/2021 | 3012.75% | Truist Securities | $150 → $127 | Maintains | Buy |
| 04/01/2021 | 2228.43% | Canaccord Genuity | $110 → $95 | Maintains | Buy |
| 04/01/2021 | 4189.22% | HC Wainwright & Co. | $185 → $175 | Maintains | Buy |
| 02/01/2021 | 2326.47% | UBS | → $99 | Initiates Coverage On | → Buy |
| 01/06/2021 | 4434.31% | HC Wainwright & Co. | $175 → $185 | Maintains | Buy |
| 11/18/2020 | 2596.08% | Canaccord Genuity | $108 → $110 | Maintains | Buy |
| 09/02/2020 | 1909.8% | Jefferies | → $82 | Initiates Coverage On | → Buy |
| 08/17/2020 | 2228.43% | BMO Capital | $104 → $95 | Maintains | Outperform |
| 08/17/2020 | 4189.22% | HC Wainwright & Co. | $200 → $175 | Maintains | Buy |
| 07/21/2020 | 2841.18% | Canaccord Genuity | $71 → $120 | Maintains | Buy |
| 07/20/2020 | 4801.96% | HC Wainwright & Co. | $120 → $200 | Maintains | Buy |
| 07/13/2020 | 1444.12% | B of A Securities | $53 → $63 | Reiterates | → Buy |
| 07/08/2020 | 2841.18% | HC Wainwright & Co. | $95 → $120 | Reiterates | → Buy |
| 06/04/2020 | 2375.49% | Guggenheim | → $101 | Initiates Coverage On | → Buy |
| 04/01/2020 | 1002.94% | B of A Securities | → $45 | Initiates Coverage On | → Buy |
| 02/26/2020 | 2228.43% | HC Wainwright & Co. | $30 → $95 | Reiterates | → Buy |
| 02/21/2020 | 1566.67% | Canaccord Genuity | $27 → $68 | Maintains | Buy |
| 02/14/2020 | 3576.47% | SunTrust Robinson Humphrey | $24 → $150 | Maintains | Buy |
| 01/08/2020 | 635.29% | HC Wainwright & Co. | $25 → $30 | Maintains | Buy |
| 11/12/2019 | 488.24% | SunTrust Robinson Humphrey | → $24 | Initiates Coverage On | → Buy |
What is the target price for BioXcel Therapeutics (BTAI)?
The latest price target for BioXcel Therapeutics (NASDAQ: BTAI) was reported by HC Wainwright & Co. on November 15, 2023. The analyst firm set a price target for $11.00 expecting BTAI to rise to within 12 months (a possible 169.61% upside). 31 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioXcel Therapeutics (BTAI)?
The latest analyst rating for BioXcel Therapeutics (NASDAQ: BTAI) was provided by HC Wainwright & Co., and BioXcel Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for BioXcel Therapeutics (BTAI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioXcel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioXcel Therapeutics was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
Is the Analyst Rating BioXcel Therapeutics (BTAI) correct?
While ratings are subjective and will change, the latest BioXcel Therapeutics (BTAI) rating was a reiterated with a price target of $0.00 to $11.00. The current price BioXcel Therapeutics (BTAI) is trading at is $4.08, which is within the analyst's predicted range.